Peptide therapy for mood and joy: what the science actually says

What did @mrs.fitskns actually say?

The creator warned that Retta, shorthand for retatrutide, will "literally kill your drive to do anything" and turn users into "emotionless zombies." The argument is that because the drug hits multiple pathways, it suppresses not just food cravings but also the dopamine-driven reward you get from things you actually enjoy. Her fix: find a source of joy before you start, because weight loss alone won't sustain you mentally.

To be fair, she is not selling anything here. She is raising a real concern that most weight-loss influencers ignore entirely, which is the psychological cost of aggressive appetite suppression. That earns some credit upfront. But the mechanistic explanation she gives, that retatrutide specifically depletes dopamine, deserves a harder look before you take it as settled science.

Does the science back this up?

Partially, but the dopamine framing is an oversimplification. Retatrutide is a triple agonist acting on GLP-1, GIP, and glucagon receptors. GLP-1 receptors are expressed in dopaminergic regions including the ventral tegmental area and nucleus accumbens, the core of the brain's reward circuitry. So yes, there is a plausible neurological mechanism here.

Research on GLP-1 receptor agonists like semaglutide has documented what some patients and clinicians call "emotional blunting" or "anhedonia." A 2023 survey-based study by Howick et al. in the journal Obesity raised anhedonia as a reported side effect worth investigating. Separate animal studies, including work by Dossat et al. (2011, American Journal of Physiology), showed GLP-1 receptor activation in the nucleus accumbens reduced motivation for palatable foods, not just hunger signals. The creator's instinct is grounded in real pharmacology. The problem is that retatrutide is still in Phase 2 and 3 trials, and the specific dopamine disruption she describes has not been formally characterized in clinical data for this compound.

What did they get wrong (or right)?

She got the concern directionally right but attributed it too cleanly to dopamine. Dopamine is not simply "motivation and reward" in a one-to-one way. That framing comes from popular neuroscience and flattens a genuinely complex system. GLP-1 agonism may reduce hedonic eating drive, but the leap from "reduced food reward" to "lost joy in everything" involves other neurotransmitter systems, including serotonin and endocannabinoids, that she does not mention.

She also says Retta "will literally kill your drive" as a universal statement. That is too strong. Anhedonia and emotional blunting are reported by a subset of GLP-1 users, not all of them. A 2024 review by Blundell et al. in Diabetes, Obesity and Metabolism noted that emotional responses to GLP-1 drugs vary considerably between individuals. Calling it a certainty is misleading.

Her practical advice, building a life with purpose before starting a weight-loss drug, is actually reasonable harm-reduction framing. It is not a clinical recommendation, but it reflects real patient experience that psychiatrists and obesity medicine physicians are beginning to take seriously.

What should you actually know?

If you are considering any GLP-1 or multi-agonist peptide therapy, the psychological side effects are a legitimate conversation to have with a prescribing clinician, not a TikTok creator. Anhedonia and motivational blunting have been reported with semaglutide and tirzepatide, the drugs closest to retatrutide in mechanism. The FDA adverse event reporting system includes cases of depression and suicidal ideation with GLP-1 drugs, though causality has not been established.

Retatrutide is not FDA approved as of mid-2025. It is not legally available through licensed telehealth platforms, and any compound being sold as retatrutide has no regulatory oversight on purity or dosing. The creator's disclaimer that this is "for research purposes only" does not change the fact that her audience is likely using this content to make real decisions.

If you are already on a GLP-1 class drug and noticing emotional flatness, that is worth reporting to your prescriber. It is not something to push through or treat as a sign the drug is working.

The bottom line

The creator identified a real and underreported concern about reward-system blunting with GLP-1 class drugs. The neuroscience she cited is plausible but presented with more certainty than the evidence supports, especially for retatrutide specifically, which lacks the long-term psychiatric safety data of older GLP-1 agents. Her advice to build purpose and joy before starting treatment is reasonable, but the framing that the drug will universally rob your dopamine is an overstatement that could scare people away from legitimate medical care or, conversely, push them toward unregulated compounds under the assumption they fully understand the risks.